Clinical trials: Melasma
Melasma
Revlite Laser System Compared to the Candela Alex TriVantage System Refractory Mixed Type Melasma
This proof of concept study will be conducted to assess the aesthetic improvement in refractory mixed type melasma in subjects treated with two FDA 510K approved devices: Q Switched Nd: YAG Laser vs. Alex TriVantage
- Trial name
- NCT01745224
- Testing
- Revlite Q switched Nd:YAG, Trivantage Q switched Nd: YAG
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Cynosure, Inc.
Melasma
A Study of the RevLite Laser System for the Treatment of Refractory Mixed Type Melasma
The purpose of this study is to compare a hydroquinone skin care regimen alone to a combination of Revlite Laser treatment with a hydroquinone skin care regimen for the treatment of melasma.
- Trial name
- NCT02110134
- Testing
- Revlite Laser System with hydroquinone skin care regimen, Hydroquinone skin care regimen
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Cynosure, Inc.
Melasma
Efficacy and Safety of PiQo4 Device for Treatment of Melasma
Single center, Prospective, Open Label with Split-face Study Design. Face sides will be randomized to receive either 1064nm alone or 1064nm \& 585nm combination treatment.
- Trial name
- NCT03565341
- Testing
- PiQo4
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Focus Medical, LLC
Facial Melasma
Efficacy and Safety of a 4% Hydroquinone Cream for the Treatment of Melasma
To assess the ability of a new 4% Hydroquinone formulation (Melanoderm 4% Crema) to reduce melasma on the face, using a split-face randomization design, evaluating the MASI Score from baseline to week 4 and week 8, in both…
- Trial name
- NCT02095990
- Testing
- Hydroquinone
- Where
- Spain
- Volunteers
- 17 people
- Sponsor
- Mesoestetic Pharma Group S.L.
Melasma
LaseMD System for the Treatment of Melasma
This study will evaluate the clinical outcomes associated with use of the LaseMD Laser System for the treatment of melasma.
- Trial name
- NCT03456674
- Testing
- LaseMD System
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- CynosureLutronic
Melasma
Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Participants With Moderate Facial Melasma
The objective of this study is to evaluate the efficacy and tolerability of Lytera 2.0 versus 4% hydroquinone in the improvement of the appearance of moderate facial melasma.
- Trial name
- NCT02977507
- Testing
- Lytera 2.0, 4% Hydroquinone Topical Cream, SkinMedica Facial Cleanser
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Allergan
Melasma
Efficacy and Safety of Picosecond, Neodymium-doped Yttrium Aluminum Garnet Laser Therapy Using 1,064 nm and 595 nm
This is a prospective, multi-center, split-face, controlled clinical trial that aims to investigate the efficacy and safety of picosecond, neodymium-doped yttrium aluminum garnet laser laser therapy on patients with melasma…
- Trial name
- NCT03040089
- Testing
- PICO+4, Neoquine Cream 2%
- Volunteers
- 40 people
- Sponsor
- CynosureLutronic
Melasma, Lentigines
A Prospective Multi-Center Study Using Laser for the Treatment of Melasma and Lentigines in Asian Skin
The purpose of this investigation is to evaluate safety and efficacy of the Cutera enlighten dual-pulse duration, dual-wavelength 532nm KTP/1064nm Nd:YAG laser for the treatment of melasma and lentigines on the face in Asian skin.
- Trial name
- NCT02385994
- Testing
- enLighten Laser
- Where
- 2 sites in China, Japan
- Volunteers
- 80 people
- Sponsor
- Cutera Inc.
Melasma
Combination Alexandrite Laser and Topical Therapy vs Topical Therapy Alone for Treatment of Melasma
The purpose of this study is to evaluate the efficacy and safety of a combination of non-hydroquinone topical therapy and a 755nm Alexandrite compared to topical therapy alone for the treatment of facial melasma.
- Trial name
- NCT02095756
- Testing
- 755nm Alexandrite Laser and Lytera Skin Brightening System (Non-Hydroquinone Topical Therapy), Lytera Skin Brightening System (Non-hydroquinone topical therapy)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cynosure, Inc.
Melasma
Melanil in the Treatment of Melasma
The purpose of the study is to assess the efficacy of Melanil facial cream in the treatment of melasma. The duration of this double-blind phase 3 clinical trial will be 54 weeks.
- Trial name
- NCT01001624
- Testing
- Melanil facial cream, Hydroquinone 2% cream
- Where
- Cuba
- Volunteers
- 150 people
- Sponsor
- Catalysis SL